Studies | Phase Ib/II for CLL/SLL | Phase Ib/II for CLL patients (N=116) [26] | Ibrutinib | Ibrutinib | ||
---|---|---|---|---|---|---|
+ | + | |||||
Rituximab | Ofatumumab | |||||
(High risk refractory/relapsed) | Treatment naïve patients >65 years old | Relapsed/refractory | High risk relapsed/refractory | (Relapsed/refractory CLL) | (Relapsed/refractory CLL) | |
[N=85] [24] | [N=40] [40] | [N=40] [41] | ||||
ORR | 71% | 71% (CR=10%, PR=61%) | 67 % (CR=3%, PR=64%) | 50% (PR=50%, CR=0%) | 85% | 100% |